-

Bruce Frank Joins Altasciences as Vice President, CDMO Operations

LAVAL, Quebec--(BUSINESS WIRE)--Altasciences announced the appointment of Dr. Bruce Frank, PhD, as Vice President, CDMO Operations. Bruce has 30 years of experience with product formulation and development, leading discovery chemistry, new technology evaluation, and project management initiatives, in both small and large biotechnology firms, making him a highly regarded leader in the CDMO space.

Bruce received a doctorate in Organic Chemistry from the University of Maryland and a bachelor’s degree in Chemistry from Temple University. He has contributed to over 45 publications, presentations, and patent disclosures in the field.

At Altasciences, Bruce will oversee the Manufacturing, Formulation, and Analytical teams, applying his most recent experience from Lubrizol Life Sciences to maximize client experience and streamline early phase drug development.

We are thrilled to welcome Bruce to the team. We know that his vast expertise in formulation adds tremendous value for our clients, getting their drug development programs started on the right foot. Bruce’s contributions will foster the excellence, innovation, and rapid delivery that Altasciences is known for,” said Ben W. Reed, Executive Vice President, CDMO Operations at Altasciences.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Altasciences

Details
Headquarters: Laval, Canada
CEO: Marie-Hélène Raigneau
Employees: 2,000+
Organization: PRI


Contacts

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

Social Media Profiles
More News From Altasciences

Altasciences Continues to Expand North American Bioanalytical Footprint

LAVAL, Québec--(BUSINESS WIRE)--Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a n...

Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania

LAVAL, Québec--(BUSINESS WIRE)--Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scient...

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

LAVAL, Québec--(BUSINESS WIRE)--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in...
Back to Newsroom